Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Schizophrenia

Interventions

DRUG

Levetiracetam

Anticonvulsant drug

DRUG

Placebo

Trial Locations (1)

Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora

All Listed Sponsors

lead

VA Office of Research and Development

FED

NCT03034356 - Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia | Biotech Hunter | Biotech Hunter